Clinicopathologic Analysis of 22 Cases of Subcutaneous Panniculitis-Like CD56- or CD56+ Lymphoma and Review of 44 Other Reported Cases

Morishige Takeshita, Shuhei Imayama, Yumi Oshiro, Kenji Kurihara, Sumika Okamoto, Yasumasa Matsuki, Yutaka Nakashima, Takashi Okamura, Motoaki Shiratsuchi, Toru Hayashi, Masahiro Kikuchi

Research output: Contribution to journalArticle

33 Citations (Scopus)


In 22 histologic cases of subcutaneous panniculitis-like lymphoma, we studied the clinicopathologic differences between CD56- and CD56+ cases (11 each). CD56- cases had skin ulcers (1 [9%]); tumor invasion in the superficial dermis (1 [9%]); erythrophagocytosis (10 [91%]); and medium-sized (11 [100%]), CD8+ (10 [91%]), T-cell receptor (TcR)βF1 + (10 [91%]), and CD95 (Fas)- tumor cells. CD56+ cases had skin ulcers (9 [82%]); tumor invasion in the superficial dermis (8 [73%]); erythrophagocytosis (1 [9%]); and pleomorphic large (10 [91%]), CD8+ (2/10 [20%]), TcRβF1 + (3/10 [30%]), and CD95 (Fas) + (7/10 [70%]) tumor cells. These 7 factors were significantly different between groups (P < .01) Median survival rates were 96 and 12 months for the CD56- and CD56+ groups, respectively. Age younger than 40 years, no skin ulcers, no tumor invasion in the superficial dermis, and CD8+, TcRβF1 +, CD95 (Fas)-, and CD56- tumor cells were significantly better prognostic factors (P < .01). The CD56- and CD56+ groups showed different tumor cell characteristics, clinicopathologic findings, and prognosis. In the CD56+ group, 1 was γ/δ T-cell phenotype, 3 were α/β T-cell, and 6 were TcRβF1- and γ/δ- NK/T-cell, and 3 NK/T-cell cases had nuclear signals of Epstein-Barr virus-encoded RNA. Cases of CD56+ T- and NK/T-cell lymphoma had similar clinicopathologic findings and prognosis.

Original languageEnglish
Pages (from-to)408-416
Number of pages9
JournalAmerican Journal of Clinical Pathology
Issue number3
Publication statusPublished - Mar 2004


All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this